UNSPSC 51341806: Sofosbuvir

Antiviral for the treatment of Hepatitis C virus infections

UNSPSC 51341806 Sofosbuvir is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent opportunities tagged under this code show limited alignment with sofosbuvir itself. State and local governments use this code to acquire prescription medications and pharmaceutical supplies through piggyback contracts, cooperative purchasing consortia, and competitive bidding processes. The issuing bodies include state departments of health and county health authorities procuring on behalf of public health programs, emergency response initiatives, and community health services. Acquisition mechanisms typically route through established pharmaceutical supply agreements (such as MMCAP Infuse) or direct competitive bids to preferred vendors, with contracts structured as annual awards with renewal options.

Recent activity appears concentrated in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, for a total contract value of $2,999,999.11 over 12 months with two additional renewal option years — though the specific products awarded (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) do not match the sofosbuvir code designation. Seminole County, Florida released an IFB (Bid Number IFB60459723LAS) posted June 30, 2026, with a response deadline of July 26, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually under a two-year initial term plus one-year renewal option. The mismatch between the code name and the products actually appearing in recent solicitations suggests this code may be misapplied in current state and local procurement systems, or sofosbuvir demand through these channels remains minimal relative to broader pharmaceutical acquisition activity.